Management of premenopausal patients with luminal A breast cancer is controversial.
Luminal A breast cancer patients are less responsive to chemotherapy.
Ovarian suppression has no added value over tamoxifen in low risk patient group.
Low risk luminal A breast cancer patients might be treated with adjuvant tamoxifen alone with good disease control.